Pillai S V, Kolluri V R, Mohanty A, Chandramouli B A
Department of Neurosurgery, National Institute of Mental Health and Neurosciences, Bangalore - 560029, India.
Neurol India. 2003 Sep;51(3):361-3.
The aim of this study was to establish whether nimodipine given orally soon after severe diffuse head injury for a period of three weeks improved outcome.
The present report analyzes the results of a prospective randomized double-blind placebo-controlled trial of nimodipine in 97 severe head injury patients (GCS Score < or =8) treated at the Department of Neurosurgery, NIMHANS, between January 1995 and June 1996. The patients were randomly assigned to two groups which were matched for age, sex, mode of injury, time interval from injury to admission, neurological status and CT scan findings. One group was given nimodipine 30 mg Q6H and the other group was given a placebo. The outcome of these patients at 6 months was evaluated using the Glasgow Outcome Score by and a psychologist.
Results showed no significant difference in the functional and psychological outcome between the two groups, even in patients with subarachnoid hemorrhage. No adverse drug events were recorded.
Oral nimodipine given for three weeks does not improve outcome in patients with severe diffuse head injury.
本研究旨在确定重度弥漫性颅脑损伤后短期内口服尼莫地平三周是否能改善预后。
本报告分析了1995年1月至1996年6月在NIMHANS神经外科治疗的97例重度颅脑损伤患者（格拉斯哥昏迷评分≤8分）中进行的一项前瞻性随机双盲安慰剂对照试验的结果。患者被随机分为两组，两组在年龄、性别、损伤方式、受伤至入院的时间间隔、神经状态和CT扫描结果方面相匹配。一组给予尼莫地平30毫克，每6小时一次，另一组给予安慰剂。6个月时由一名心理学家使用格拉斯哥预后评分对这些患者的预后进行评估。
结果显示，两组之间在功能和心理预后方面无显著差异，即使是蛛网膜下腔出血患者。未记录到不良药物事件。
重度弥漫性颅脑损伤患者口服尼莫地平三周并不能改善预后。
Zotero 插件